Bisphosphonate-induced femoral fragility fractures: What do we know?

isphosphonate-induced femoral fragility fractures: What do we know? Review (7048) Total Article Views Authors: Arkan S Sayed-Noor, Bakir K Kadum, G ran O Sj dén Published Date March 2010 Volume 2010:2 Pages 27 - 34 DOI: http://dx.doi.org/10.2147/ORR.S7521 Arkan S Sayed-Noor1,2, Bakir K Kadum1, G ran O Sj dén1,2 1Department of Orthopaedic Surgery, Sundsvall Hospital, Sundsvall, Sweden; 2Department of Surgical and Perioperative Sciences, Norrlands University Hospital, Ume , Sweden Abstract: Bisphosphonates (BPs), in particular alendronate, are the cornerstone of treatment for postmenopausal osteoporosis. The efficacy and safety of these drugs are well documented in the literature. However, increasing numbers of reports show a possible association between long-term treatment with BPs and the occurrence of characteristic femoral fragility fractures. In this review article, we discuss the existing reports in regard to the natural history and management of these fractures. Orthopedic surgeons and other specialists dealing with patients on BP therapy should be aware of this possible association because patients with BP-induced femoral fragility fractures warrant prompt surgical management.